492 related articles for article (PubMed ID: 1960490)
21. Metabolism and proliferation of cultured fibroblasts from specimens of human palmar fascia and Dupuytren's contracture. The pathobiochemistry of connective tissue proliferation, II.
Delbrück A; Schröder H
J Clin Chem Clin Biochem; 1983 Jan; 21(1):11-7. PubMed ID: 6854215
[TBL] [Abstract][Full Text] [Related]
22. [The pathobiochemistry of Dupuytren's contracture].
Bobiński R
Chir Narzadow Ruchu Ortop Pol; 2009; 74(2):68-73. PubMed ID: 19514484
[TBL] [Abstract][Full Text] [Related]
23. Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords.
Dave SA; Banducci DR; Graham WP; Allison GM; Ehrlich HP
Exp Mol Pathol; 2001 Oct; 71(2):147-55. PubMed ID: 11599921
[TBL] [Abstract][Full Text] [Related]
24. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells.
Vi L; Feng L; Zhu RD; Wu Y; Satish L; Gan BS; O'Gorman DB
Exp Cell Res; 2009 Dec; 315(20):3574-86. PubMed ID: 19619531
[TBL] [Abstract][Full Text] [Related]
25. Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.
Verjee LS; Midwood K; Davidson D; Eastwood M; Nanchahal J
J Cell Physiol; 2010 Sep; 224(3):681-90. PubMed ID: 20432463
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
27. Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts.
Satish L; Gallo PH; Baratz ME; Johnson S; Kathju S
BMC Musculoskelet Disord; 2011 May; 12():113. PubMed ID: 21612641
[TBL] [Abstract][Full Text] [Related]
28. Cytokine manipulation of explanted Dupuytren's affected human palmar fascia.
Kuhn MA; Payne WG; Kierney PC; Pu LL; Smith PD; Siegler K; Ko F; Wang X; Robson MC
Int J Surg Investig; 2001; 2(6):443-56. PubMed ID: 12678125
[TBL] [Abstract][Full Text] [Related]
29. Scientific comment. Basic science of Dupuytren's disease.
Murrell GA
Ann Chir Main Memb Super; 1992; 11(5):355-61. PubMed ID: 1284015
[TBL] [Abstract][Full Text] [Related]
30. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro.
Moyer KE; Banducci DR; Graham WP; Ehrlich HP
Plast Reconstr Surg; 2002 Jul; 110(1):187-93; discussion 194-6. PubMed ID: 12087251
[TBL] [Abstract][Full Text] [Related]
31. Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts.
Wong M; Mudera V
J Hand Surg Br; 2006 Oct; 31(5):473-83. PubMed ID: 16875762
[TBL] [Abstract][Full Text] [Related]
32. Responsiveness of Dupuytren's disease fibroblasts to 5 alpha-dihydrotestosterone.
Pagnotta A; Specchia N; Soccetti A; Manzotti S; Greco F
J Hand Surg Am; 2003 Nov; 28(6):1029-34. PubMed ID: 14642522
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-beta1 stimulation enhances Dupuytren's fibroblast contraction in response to uniaxial mechanical load within a 3-dimensional collagen gel.
Bisson MA; Beckett KS; McGrouther DA; Grobbelaar AO; Mudera V
J Hand Surg Am; 2009; 34(6):1102-10. PubMed ID: 19505772
[TBL] [Abstract][Full Text] [Related]
34. Fine structural alterations of the palmar aponeurosis in Dupuytren's contracture. A combined scanning and transmission electronmicroscopic examination.
Józsa L; Salamon A; Réffy A; Renner A; Demel S; Donhöffer A; Pintér T; Thöring J
Zentralbl Allg Pathol; 1988; 134(1):15-25. PubMed ID: 3358315
[TBL] [Abstract][Full Text] [Related]
35. Cell-controlling factors in Dupuytren's contracture.
Hueston JT; Murrell GA
Ann Chir Main Memb Super; 1990; 9(2):135-7. PubMed ID: 1695516
[TBL] [Abstract][Full Text] [Related]
36. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
Bianchi E; Taurone S; Bardella L; Signore A; Pompili E; Sessa V; Chiappetta C; Fumagalli L; Di Gioia C; Pastore FS; Scarpa S; Artico M
Clin Sci (Lond); 2015 Oct; 129(8):711-20. PubMed ID: 26201022
[TBL] [Abstract][Full Text] [Related]
37. Aetiology of Dupuytren's contracture.
Murrell GA; Hueston JT
Aust N Z J Surg; 1990 Apr; 60(4):247-52. PubMed ID: 2322211
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease.
Ulrich D; Ulrich F; Piatkowski A; Pallua N
Arch Orthop Trauma Surg; 2009 Nov; 129(11):1453-9. PubMed ID: 18758795
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro.
Rayan GM; Parizi M; Tomasek JJ
J Hand Surg Am; 1996 Nov; 21(6):1065-70. PubMed ID: 8969433
[TBL] [Abstract][Full Text] [Related]
40. Dupuytren's disease susceptibility gene, EPDR1, is involved in myofibroblast contractility.
Staats KA; Wu T; Gan BS; O'Gorman DB; Ophoff RA
J Dermatol Sci; 2016 Aug; 83(2):131-7. PubMed ID: 27245865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
